Nurix Therapeutics, Inc.
NRIX • NASDAQ
Nurix Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Arthur T. Sands, with a market cap of $1.5B.
CEOArthur T. Sands
Next Earnings
Upcoming earnings announcement for Nurix Therapeutics, Inc.
Date
Friday, April 10, 2026 (in 1 week)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.76
Revenue Estimate
$14.4M
Earnings History
Past 12 earnings reports for Nurix Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Jan 28, 2026 | Q4 2025 | -$0.82Est: -$0.89 | +7.9% | $13.6MEst: $15.2M | -10.7% |  10-K |
| Oct 9, 2025 | Q3 2025 | -$1.03Est: -$0.85 | -21.2% | $7.9MEst: $17.1M | -53.8% | 10-Q |
| Jul 9, 2025 | Q2 2025 | -$0.52Est: -$0.75 | +30.7% | $44.1MEst: $16.9M | +160.8% | 10-Q |
| Apr 8, 2025 | Q1 2025 | -$0.67Est: -$0.78 | +14.1% | $18.5MEst: $12.7M | +45.2% | 10-Q |
| Jan 28, 2025 | Q4 2024 | -$0.75Est: -$0.71 | -5.6% | $13.3MEst: $12.9M | +3.3% | 10-K |
| Oct 11, 2024 | Q3 2024 | -$0.67Est: -$0.72 | +6.9% | $12.6MEst: $15.8M | -20.1% | 10-Q |
| Jul 11, 2024 | Q2 2024 | -$0.71Est: -$0.64 | -10.9% | $12.1MEst: $22.9M | -47.2% | 10-Q |
| Apr 10, 2024 | Q1 2024 | -$0.76Est: -$0.80 | +5.0% | $16.6MEst: $16.6M | -0.3% | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$0.77Est: -$0.57 | -35.1% | $15.2MEst: $22.3M | -31.9% | 10-K |
| Oct 12, 2023 | Q3 2023 | -$0.68Est: -$0.76 | +10.5% | $18.5MEst: $17.2M | +7.2% | 10-Q |
| Jul 13, 2023 | Q2 2023 | -$0.45Est: -$0.56 | +19.6% | $30.7MEst: $26.2M | +17.0% | — |
| Apr 13, 2023 | Q1 2023 | -$0.75Est: -$0.87 | +13.8% | $12.7MEst: $10.9M | +16.7% | — |